Your browser doesn't support javascript.
loading
Characterization of the cell-mediated immune response to Takeda's live-attenuated tetravalent dengue vaccine in adolescents participating in a phase 2 randomized controlled trial conducted in a dengue-endemic setting.
Tricou, Vianney; Gottardo, Raphael; Egan, Michael A; Clement, Frédéric; Leroux-Roels, Geert; Sáez-Llorens, Xavier; Borkowski, Astrid; Wallace, Derek; Dean, Hansi J.
Afiliación
  • Tricou V; Takeda Pharmaceuticals International AG, Zurich, Switzerland. Electronic address: vianney.tricou@takeda.com.
  • Gottardo R; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Egan MA; Takeda Vaccines Inc., Cambridge, MA, USA.
  • Clement F; Center for Vaccinology (CEVAC), University Hospital, Ghent, Belgium.
  • Leroux-Roels G; Center for Vaccinology (CEVAC), University Hospital, Ghent, Belgium.
  • Sáez-Llorens X; Hospital del Niño Dr. José Renán Esquivel, Panama City, Panama; Sistema Nacional de Investigación, SENACYT, Panama City, Panama; Cevaxin Research Center, Panama City, Panama.
  • Borkowski A; Takeda Pharmaceuticals International AG, Zurich, Switzerland.
  • Wallace D; Takeda Vaccines Inc., Cambridge, MA, USA.
  • Dean HJ; Takeda Vaccines Inc., Cambridge, MA, USA.
Vaccine ; 40(8): 1143-1151, 2022 02 16.
Article en En | MEDLINE | ID: mdl-35078666

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Dengue / Virus del Dengue / Vacunas contra el Dengue Tipo de estudio: Clinical_trials Límite: Adolescent / Humans Idioma: En Revista: Vaccine Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Dengue / Virus del Dengue / Vacunas contra el Dengue Tipo de estudio: Clinical_trials Límite: Adolescent / Humans Idioma: En Revista: Vaccine Año: 2022 Tipo del documento: Article